Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...

AUSTIN, Texas - Natera, Inc. (NASDAQ:NTRA) announced Tuesday a new multi-modal artificial intelligence model designed to improve molecular residual disease (MRD) assessment in cancer patients. The ...

AUSTIN, Texas - Natera, Inc. (NASDAQ:NTRA) announced that data from its EXPAND clinical trial will be featured in an oral plenary presentation at the Society for Maternal-Fetal Medicine (SMFM) meeting ...

AUSTIN, Texas, January 21, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication in npj Precision Oncology of the ...

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and fiscal year of 2025, provided an update on progress toward achieving key corporate objectives, and outlined ...

All right. Great. Looks like we can get started here. Hi, everybody. Welcome to JPMorgan Healthcare Conference. My name is Casey Woodring from Life Science Tools and Diagnostics team. Pleased to be ...

Shimla: The Himachal Pradesh govt will soon formulate a state nutrition policy to ensure access to balanced and nutritious food for vulnerable groups, including children, adolescent girls, and ...

Following these results, Canaccord Genuity reiterated its Buy rating for Natera, maintaining a price target of $285.00. Additionally, Natera announced a collaboration with Exelixis on a phase 3 trial ...

The United States Food and Drug Administration recently approved Tonmya TM (cyclobenzaprine hydrochloride sublingual tablets) ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year ...